IP Library › Granted Patent US 8,604,166
Granted Patent B2
US 8,604,166 · App. 13/060,484 · Granted Dec 10, 2013

Melanoma antigen peptide and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,604,166
App. No.
13/060,484
Granted
Dec 10, 2013
Kind
B2
Abstract

The present invention relates to novel melanoma antigen peptides and specific T lymphocytes directed to said peptides and the use thereof for treating melanoma.

Claims (9)

1. A melanoma antigen peptide having an amino acid sequence that is less than 50 amino acids in length and comprising SEQ ID NO:2:

TX 2 NDECWPX 9

(SEQ ID NO: 2)

wherein X 2 is leucine, methionine, valine, isoleucine or glutamine and X 9 is alanine, valine or leucine.

2. A melanoma antigen peptide according to claim 1 , wherein said melanoma antigen peptide is MELOE-1 having the sequence SEQ ID NO: 4.

3. A melanoma antigen peptide according to claim 1 , wherein said melanoma antigen peptide is selected in the group consisting of peptides having the sequence SEQ ID NO: 6 to SEQ ID NO: 20.

4. A MHC/peptide multimer comprising a melanoma antigen peptide according to claim 3 .

5. An immunising composition comprising

at least one melanoma antigen peptide according to claim 1 .

Assignments (2)
MERGER Recorded Sep 7, 2023
From: UNIVERSITE DE NANTES
To: NANTES UNIVERSITE
Reel/Frame 064824/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 3, 2011
From: LABARRIERE, NATHALIE; MOREAU-AUBRY, AGNES; GODET, YANN
To: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE); UNIVERSITE DE NANTES; CHU NANTES
Reel/Frame 026215/0973 →